Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.

Journal of viral hepatitis - 1 Aug 2014

van der Meer A J, Veldt B J, Feld J J, Wedemeyer H, Dufour J-F, Lammert F, Duarte-Rojo A, Manns M P, Zeuzem S, Hofmann W P, de Knegt R J, Hansen B E, Janssen H L A

Abstract excerpt

Cirrhotic patients with chronic hepatitis C virus (HCV) infection remain at risk for complications following sustained virological response (SVR). Therefore, we aimed to evaluate treatment efficacy with the number needed to treat (NNT) to prevent clinical endpoints. Mortality and cirrhosis-related morbidity were assessed in an international multicentre cohort of consecutively treated patients with HCV genotype 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to International Cooperation

Share to Liver Cirrhosis

Share to Survival Analysis

Source

Identifiers

PMID: 24118177
DOI: 10.1111/jvh.12185

Genes

NNT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.PMID 24118177Read ↗

How to optimize HCV therapy in genotype 1 patients with cirrhosis.Semantic proximity Read ↗

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.Semantic proximity Read ↗

Cause-Specific Mortality Following Sustained Virologic Response in hepatitis C patients Treated with Direct-Acting Antivirals: A Standardized Mortality Ratio AnalysisSemantic proximity Read ↗

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

Effect of sustained viral clearance on liver-related mortality among individuals living with hepatitis C by treatment era: a population-based retrospective cohort studySemantic proximity Read ↗

The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCVSemantic proximity Read ↗

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.Semantic proximity Read ↗

[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].Semantic proximity Read ↗

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.Semantic proximity Read ↗

Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype.Semantic proximity Read ↗

Is the benefit of treating patients with cirrhosis proven?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.